X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (64) 64
humans (54) 54
female (52) 52
oncology (36) 36
breast neoplasms - drug therapy (34) 34
breast cancer (32) 32
middle aged (26) 26
chemotherapy (25) 25
adult (19) 19
cancer (18) 18
article (17) 17
chemotherapy, adjuvant (17) 17
trastuzumab (16) 16
breast neoplasms - pathology (15) 15
aged (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
neoadjuvant therapy (12) 12
clinical trials (11) 11
health aspects (11) 11
research (11) 11
cyclophosphamide - administration & dosage (10) 10
disease-free survival (10) 10
prognosis (10) 10
surgical adjuvant breast (10) 10
treatment outcome (10) 10
breast neoplasms - mortality (9) 9
cancer therapies (9) 9
docetaxel (9) 9
drug therapy (9) 9
neoplasm staging (9) 9
analysis (8) 8
animals (8) 8
antibodies, monoclonal, humanized - administration & dosage (8) 8
antineoplastic agents - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
breast neoplasms - metabolism (8) 8
care and treatment (8) 8
cells (8) 8
doxorubicin - administration & dosage (8) 8
follow-up studies (8) 8
receptor, erbb-2 - metabolism (8) 8
risk (8) 8
survival (8) 8
women (8) 8
cyclophosphamide (7) 7
doxorubicin (7) 7
hematology, oncology and palliative medicine (7) 7
medicine, general & internal (7) 7
neoadjuvant chemotherapy (7) 7
original reports (7) 7
surgery (7) 7
tamoxifen (7) 7
taxoids - administration & dosage (7) 7
therapy (7) 7
usage (7) 7
bevacizumab (6) 6
breast neoplasms - surgery (6) 6
mastectomy (6) 6
paclitaxel (6) 6
paclitaxel - administration & dosage (6) 6
preoperative chemotherapy (6) 6
survival analysis (6) 6
survival rate (6) 6
abridged index medicus (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents - administration & dosage (5) 5
breast neoplasms - enzymology (5) 5
deoxycytidine - administration & dosage (5) 5
deoxycytidine - analogs & derivatives (5) 5
diagnosis (5) 5
endocrine therapy (5) 5
gene expression (5) 5
neoplasm recurrence, local - drug therapy (5) 5
neoplasm recurrence, local - pathology (5) 5
obstetrics & gynecology (5) 5
outcomes (5) 5
patients (5) 5
postmenopausal women (5) 5
pregnancy (5) 5
prevention (5) 5
risk factors (5) 5
trial (5) 5
tumors (5) 5
young adult (5) 5
acetyltransferases - metabolism (4) 4
adjuvant treatment (4) 4
adolescent (4) 4
anthracycline (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
aromatase inhibitors (4) 4
biochemical-action (4) 4
biochemistry & molecular biology (4) 4
body mass index (4) 4
breast neoplasms - therapy (4) 4
case-control studies (4) 4
chlamydia infections - complications (4) 4
chlamydia trachomatis (4) 4
cytokines (4) 4
erbb-2 protein (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Applied Radiology, ISSN 0160-9963, 11/2007, Volume 36, Issue 11, p. 62
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Entomologia Experimentalis et Applicata, ISSN 0013-8703, 12/2019, Volume 167, Issue 12, pp. 1012 - 1019
Ant‐lycaenid associations range from mutualism to parasitism and the caterpillars of some species of lycaenids are reported to enter ant nests for shelter,... 
cowpea | Formicidae | extrafloral nectary‐bearing crop plant | ant‐lycaenid association | Vigna unguiculata | Lepidoptera | Euchrysops cnejus | Hymenoptera | Lycaenidae | Camponotus compressus | Fabaceae
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 156 - 163
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 31, pp. 3792 - 3799
Journal Article
Statistics in Medicine, ISSN 0277-6715, 02/2019, Volume 38, Issue 3, pp. 301 - 314
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
PROJECT PROTOCOL B-27 | TRIAL | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | THERAPY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | PHASE-III | DISEASE | DOCETAXEL | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article